DDrare: Database of Drug Development for Rare Diseases

Searched query = "Pemphigus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ALXN1830; ARGX-113; Acetaminophen; Acetaminophen/paracetamol; Acetate; Antihistamine (cetirizine or equivalent); Azathioprine; CELLCEPT®; CORTANCYL 20 mg; Carboxymethylcellulose; CellCept 500 mg comprimidos recubiertos; CellCept®500 mg comprimidos; Cellcept® in autoimmune bullous dermatoses; Cellulose; Cetirizine; Cohort 1: 1.0 x 10^8 PolyTregs; Cohort 2: 2.5x10^8 PolyTregs; Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine; Cortancyl; Corticosteroids'therapy; Cotton; Cyclophosphamide; DSG3-CAART; Dapsone; Dermoval; Device: Carboxymethylcellulose with ionic silver (Aquacel Ag); Device: Cellulose acetate with petrolatum; Device: Cotton gauze with petrolatum; Device: Nanocrystalline silver (Acticoat); Dexamethasone; Dexamethasone (50mg 1dd6, 3 consecutive days/month); Dexamethasone 0.5mg/5ml solution; Dexamethasone 0.5mg/5ml solution in Mucolox™; EFGARTIGIMOD ALFA; Efgartigimod; Efgartigimod PH20 SC; Efgartigimod alfa; Enbrel (Etanercept); Etanercept; Filgrastim; GLYCINE; GSK1841157; General Corticotherapy; Glycine; Hematopoietic stem cell transplantation; Human interleukin-2; INCB050465; INCB050465 0.3 mg; INCB050465 0.3mg; INCB050465 1.0 mg; INCB050465 1.0mg; INCB050465 2.5mg; INCB050465 HYDROCHLORIDE; INTERLEUKIN-2; IVIg; Ianalumab; Imatinib; Infliximab; Intratect; Intratect 5%; Intravenous immunoglobulin; KC706; MABTHERA; MABTHERA®; MMF; MTX; MabThera; Mabthera; Mabthéra; Mathéra; Methotrexate; Methylprednisolone; Micofenolato mofetilo; Mycophenolate; Mycophenolate Mofetil; Mycophenolate Mofetil (MMF) 3 g/Day; Mycophenolate Mofetil 2 g/Day; Mycophenolate mofetil; OFATUMUMAB; ONO-4059; Ofatumumab; Other: Autologous Platelet rich plasma; Other: IVIg; PI-0824; PREDNISONE; PRN1008; PRN1008 (Rilzabrutinib); PRN1008 Freebase; PRN1008 Oral Tablet; Paracetamol; Parsaclisib; Petrolatum; Prednisolone; Prednisone; Prednisone/Prednisolone; RITUXIMAB; RO0452294/V02; RO1061443/F02; Rapamycin; Recombinant human interleukin-2 (rhIL-2); Rituximab; Rituximab (MABTHERA® or RITUXAN®).; Rituximab and Cyclophosphamide IV; Silver; Sirolimus; Sirolimus (formerly known as Rapamycin); TPM203; Tirabrutinib; Triamcinolone; Triamcinolone Acetonide; VAY736; WATER FOR INJECTION; Water; [NA]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-000382-41-IT (EUCTR)	12/03/2015	02/02/2015	A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris	A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris - PEMPHIX	Pemphigus Vulgaris (PV) MedDRA version: 17.1;Level: LLT;Classification code 10052802;Term: Pemphigus vulgaris;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]	Trade Name: MABTHERA ® Product Name: Rituximab Product Code: RO0452294/V02 INN or Proposed INN: RITUXIMAB Trade Name: CELLCEPT® Product Name: Mycophenolate mofetil Product Code: RO1061443/F02 INN or Proposed INN: Mycophenolate mofetil	F. Hoffmann-La Roche Ltd	NULL	Not Recruiting			Female: yes Male: yes	124	Phase 3	United States;France;Canada;Argentina;Spain;Ukraine;Turkey;Australia;Israel;Germany;Italy
2	NCT00960713 (ClinicalTrials.gov)	June 2009	16/7/2009	The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders	The RITAI Cohort. An Observational Study on Serious Adverse Events Occuring After Rituximab Off-label Use for Auto-immune Disorders	Pemphigus;Auto-immune Thrombocytopenic Purpura;Hemolytic Auto-immune Anaemia;Cold Agglutinin Disease;Cryoglobulinemia	Drug: Rituximab (MABTHERA® or RITUXAN®).	University Hospital, Toulouse	NULL	Completed	18 Years	N/A	Both	35	N/A	France
3	EUCTR2008-005266-31-FR (EUCTR)	06/02/2009	13/03/2009	COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III	COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III	Pemphogoide bulleuse MedDRA version: 9.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid	Trade Name: mabthéra Product Name: mathéra Trade Name: Prednisone Product Name: CORTANCYL 20 mg	CHU-Hôpitaux de Rouen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2014-000382-41-IT
(EUCTR)

12/03/2015

02/02/2015

A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris

A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris - PEMPHIX

Pemphigus Vulgaris (PV)
MedDRA version: 17.1;Level: LLT;Classification code 10052802;Term: Pemphigus vulgaris;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

Trade Name: MABTHERA ®
Product Name: Rituximab
Product Code: RO0452294/V02
INN or Proposed INN: RITUXIMAB
Trade Name: CELLCEPT®
Product Name: Mycophenolate mofetil
Product Code: RO1061443/F02
INN or Proposed INN: Mycophenolate mofetil

F. Hoffmann-La Roche Ltd

NULL

Not Recruiting

Female: yes
Male: yes

124

Phase 3

United States;France;Canada;Argentina;Spain;Ukraine;Turkey;Australia;Israel;Germany;Italy

NCT00960713
(ClinicalTrials.gov)

June 2009

16/7/2009

The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders

The RITAI Cohort. An Observational Study on Serious Adverse Events Occuring After Rituximab Off-label Use for Auto-immune Disorders

Pemphigus;Auto-immune Thrombocytopenic Purpura;Hemolytic Auto-immune Anaemia;Cold Agglutinin Disease;Cryoglobulinemia

Drug: Rituximab (MABTHERA® or RITUXAN®).

University Hospital, Toulouse

NULL

Completed

18 Years

N/A

Both

N/A

France

EUCTR2008-005266-31-FR
(EUCTR)

06/02/2009

13/03/2009

COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III

Pemphogoide bulleuse
MedDRA version: 9.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid

Trade Name: mabthéra
Product Name: mathéra
Trade Name: Prednisone
Product Name: CORTANCYL 20 mg

CHU-Hôpitaux de Rouen

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

France